Skip to content
My WebMD Sign In, Sign Up

Multiple Sclerosis Health Center

Font Size

Zocor Treats Multiple Sclerosis

Cholesterol Drug Reduces Size, Number of Brain Lesions

WebMD Health News

April 2, 2003 (Honolulu) -- Researchers have presented the first human findings looking at a cholesterol-lowering drug for multiple sclerosis treatment. They found that Zocor not only reduces the size but also the number of brain lesions from MS.

In multiple sclerosis, cells in the immune system destroy the protective lining -- called myelin -- of nerves in the brain and spinal cord.

Animal research touting cholesterol-lowering drugs called "statins" as a multiple sclerosis treatment hit the scene just last year, and the research has quickly moved from mice to humans. In a recent animal study, researchers found that Lipitor -- another statin -- prevented disease progression and reversed paralysis in mice with a multiple sclerosis-like disease.

In the current study, Timothy Vollmer, MD, and colleagues studied 28 people with the most common form of multiple sclerosis, called relapsing-remitting -- in which periods of relapse, when symptoms flare up, alternate with periods of remission, when symptoms fade. Vollmer, chairman of the division of neurology at the Barrow Neurological Institute in Phoenix, presented the results in Honolulu at the annual conference of the American Academy of Neurology.

The study participants -- aged 18 to 55 -- had evidence of at least one brain lesion from multiple sclerosis on an MRI brain scan. Each participant then took 80 mg of Zocor daily and underwent a series of MRI brain scans during the study. The study was supported by Merck Inc., Zocor's manufacturer.

Six months into treatment, the researchers found that the number of brain lesions was reduced by 43%. In addition, the researchers projected that Zocor would decrease the annual rate of relapses from 43% before treatment to 32% after treatment.

Zocor as a multiple sclerosis treatment was well tolerated by the patients, Vollmer says. "No patient stopped due to side effects."

When used to lower cholesterol, Zocor and other statins can occasionally raise liver enzymes -- indicating that the drug may be harming the liver. In this study, two of the patients had mildly elevated liver tests, which resolved after stopping the drug, says Vollmer.

Vollmer says he believes Zocor and other statins may work by suppressing an overactive part of the immune system.

"Anything that suppresses seems to be helpful," he says, and research on mice and rats has shown statins to be effective at suppressing inflammatory cells from entering the brain.

One possible additional benefit of the drug, Vollmer says, is that it appears that Zocor might be able to enter the brain to work directly on key target sites. If so, that raises the possibility that Zocor may be an effective multiple sclerosis treatment for slowing progression of the disease, Vollmer says.

But even though the study indicates that there may be a role for statins in multiple sclerosis treatment one way or another, exactly how they would be used still has to be worked out, Vollmer says.

Today on WebMD

brain and teriflunomide molecule
ARTICLE
neural fiber
ARTICLE
 
white blood cells
VIDEO
linguini with asparagus and mushrooms
ARTICLE
 
brain scan
ARTICLE
worried woman
ARTICLE
 
person writin in a notebook
ARTICLE
couple embracing
ARTICLE
 
man with cane
SLIDESHOW
skull and neck xray
ARTICLE
 
Stressed man
ARTICLE
doctor feeling patients neck
ASSESSMENT